Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors

Next Previous
X
Search
Trial Profile

A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Lung cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Apr 2022 Combined results of phase II studies (NCT03278405 and NCT03278379) assessing the efficacy and safety of avelumab, a PD-L1-directed antibody, in patients with advanced unresectable/metastatic higher grade NENs, published in the European Journal of Cancer.
    • 17 Mar 2020 Status changed from recruiting to active, no longer recruiting.
    • 19 Sep 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top